{"id":"walvax-pcv13-tt","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3975020","moleculeType":"Small molecule","molecularWeight":"475.60"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by introducing antigens from 13 serotypes of Streptococcus pneumoniae to the body, which triggers the production of antibodies to fight the bacteria. This provides immunity against invasive pneumococcal disease, including pneumonia, meningitis, and sepsis.","oneSentence":"Walvax PCV13-TT is a conjugate vaccine that stimulates the body's immune response to protect against pneumococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:55.963Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae"}]},"trialDetails":[{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Walvax PCV13-TT","genericName":"Walvax PCV13-TT","companyName":"Walvax Biotechnology Co., Ltd.","companyId":"walvax-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Walvax PCV13-TT is a 13-valent pneumococcal polysaccharide conjugate vaccine used to study pneumococcal infections, pneumococcal disease, and invasive pneumococcal infections. It is a small molecule vaccine developed by Sinovac Biotech Co., Ltd.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}